Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Nishida Y;Nishida Y; Knudson CB; Knudson W
- Source:
Osteoarthritis and cartilage [Osteoarthritis Cartilage] 2004 May; Vol. 12 (5), pp. 374-82.
- Publication Type:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
- Language:
English
- Additional Information
- Source:
Publisher: W.B. Saunders For The Osteoarthritis Research Society Country of Publication: England NLM ID: 9305697 Publication Model: Print Cited Medium: Print ISSN: 1063-4584 (Print) Linking ISSN: 10634584 NLM ISO Abbreviation: Osteoarthritis Cartilage Subsets: MEDLINE
- Publication Information:
Publication: London : W.B. Saunders For The Osteoarthritis Research Society
Original Publication: London : Published for the Society by Baillère Tindall, c1993-
- Subject Terms:
- Abstract:
Objective: To examine the capacity of recombinant osteogenic protein-1 (OP-1) to inhibit the cartilage extracellular matrix damage that follows treatment with hyaluronan hexasaccharides (HA6).
Design: The effects of OP-1 were examined on isolated human chondrocytes grown in alginate beads as well as articular cartilage slices treated with hyaluronan hexasaccharides. Changes in the relative expression of messenger RNA for hyaluronan synthase- 2, aggrecan and CD44 were determined by competitive quantitative reverse transcriptase-polymerase chain reaction. Cartilage proteoglycan biosynthesis was examined by a (35)S-sulfate incorporation assay. Cell-associated matrix of human chondrocytes was visualized by the use of particle exclusion assay, and alcian blue staining. Cartilage slices were examined for accumulation of proteoglycan by Safranin-O, and hyaluronan by a specific biotinylated probe.
Results: Combined OP-1 and HA6 treatment resulted in enhanced expression of mRNA for aggrecan and HAS-2, compared to the treatment with HA6 only. This increased expression of aggrecan mRNA was paralleled by an increased synthesis of cartilage proteoglycan especially retained in the cell-associated matrix. Co-treatment with OP-1 inhibited the HA6-induced depletion of cell-associated matrices as well as HA6-induced depletion of hyaluronan and proteoglycan within cartilage tissue slices.
Conclusions: These results demonstrate that OP-1 can abrogate the catabolic events associated with a HA6-induced matrix depletion model of osteoarthritis. The mRNA levels of two major cartilage extracellular matrix components, aggrecan and hyaluronan synthase-2 are enhanced above values obtained by either OP-1 or HA6 treatments alone.
- Grant Information:
P50 AR 39239 United States AR NIAMS NIH HHS; R01 AR 39507 United States AR NIAMS NIH HHS; R01 AR 43384 United States AR NIAMS NIH HHS
- Accession Number:
0 (Aggrecans)
0 (BMP7 protein, human)
0 (Bone Morphogenetic Protein 7)
0 (Bone Morphogenetic Proteins)
0 (Extracellular Matrix Proteins)
0 (Hyaluronan Receptors)
0 (Lectins, C-Type)
0 (Proteins)
0 (Proteoglycans)
0 (Transforming Growth Factor beta)
63231-63-0 (RNA)
9004-61-9 (Hyaluronic Acid)
EC 2.- (Transferases)
EC 2.4.1.17 (Glucuronosyltransferase)
EC 2.4.1.212 (HAS2 protein, human)
EC 2.4.1.212 (Hyaluronan Synthases)
EC 2.7.11.30 (ACVR1 protein, human)
EC 2.7.11.30 (Activin Receptors, Type I)
- Publication Date:
Date Created: 20040420 Date Completed: 20040802 Latest Revision: 20171116
- Publication Date:
20221213
- Accession Number:
10.1016/j.joca.2004.01.008
- Accession Number:
15094136
No Comments.